Cuba and Russia plan to establish first biopharmaceutical joint venture this year

Havana, March 4 (RHC) Cuba and Russia are planning to establish their first joint venture in the field of biopharmaceuticals this year, which will contribute to the expansion of Cuban products in the Russian market.

In this context, the first vice president of BioCubaFarma, Eulogio Pimentel, along with other senior executives from Cuban pharmaceutical companies, met with representatives of Russian pharmaceutical companies in Moscow.

The meeting was attended by approximately twenty organizations dedicated to the manufacturing, distribution, and promotion of pharmaceutical products and medical supplies.

The Cuban representatives showcased the progress made in their manufacturing sector, highlighting products like Heberprot-P for treating diabetic foot ulcers, and Hebermin, a tissue regenerator, which are now available in Russia.

Meanwhile, Russia is working on obtaining regulatory approval for Nimotuzumab, a monoclonal antibody used in cancer treatment.

Furthermore, it is developing projects involving novel vaccines and treatments, including the clinical development of the therapeutic vaccine against lung cancer cimavax; and Jusvinza, a medication for autoimmune disorders.

According to BioCubaFarma, the partnership is conducted in two ways: the exchange of Cuban technologies for the benefit of the Russian population, and the registration of Russian pharmaceutical products that will enhance health care in Cuba. (Source: Granma)